#Sweden #Stockholm #Nevisense #SciBase #Bergs Securities

SciBase Completes Successful Rights Issue

On October 1, 2026, SciBase Holding AB, a pioneering medical technology firm, declared the successful outcome of its rights issue, which was designed to raise approximately SEK 57.5 million. This announcement marks a significant milestone as the firm prepares to further its commercial endeavors, particularly in the U.S. market.

Details of the Rights Issue

The framework for the rights issue was set in motion by the Board of Directors' resolution on September 3, 2026, with approval from the Annual General Meeting held on May 19, 2026. The subscription window was open from September 15 to September 29, 2026. The results revealed a robust commitment from both existing shareholders and new investors, with 2,681,085 shares, amounting to approximately SEK 40.2 million, subscribed for via subscription rights. Additionally, 133,116 shares were subscribed without support from rights, totaling around SEK 2.0 million. This brings the total subscriptions to 2,814,201 shares, representing a significant 73.4 percent of the rights issue.

To fully realize the rights issue, Bergs Securities AB intervened with a guarantee of approximately SEK 15.3 million, ensuring that any remaining shares that weren't bought by existing shareholders were accounted for. With this engagement, the rights issue was fully subscribed, allowing SciBase to secure necessary funds for its operations.

Funding for Future Growth

The funds raised will be utilized to bolster SciBase’s market position in melanoma diagnostics, primarily targeting the U.S. marketplace. The CEO of SciBase, Pia Renaudin, expressed gratitude towards shareholders for their confidence and clarified that this capital influx will facilitate crucial steps, particularly in achieving reimbursement milestones and enhancing collaborations, notably with Castle Biosciences.

Jesper Høiland, Chairman of the Board, highlighted the strong shareholder backing as a testament to the company’s robust standing and performance across U.S. and German markets. The new capital infusion positions SciBase favorably for its imminent transition of CEO and steers the company towards its next phase of growth.

Shareholder Participation and Allotment

The subscription price was established at SEK 15 per share as part of the rights issue. After deducting expected issue costs of around SEK 4.8 million, the net proceeds will primarily support commercial activities focusing on the U.S. market.

Allotments of shares that were subscribed without rights will align with the principles published in the information document on September 14, 2026. Investors will receive notifications via contract notes regarding the shares allotted to them.

Trading Updates

Shares in the rights issue are expected to continue trading on Nasdaq First North Growth Market until the transaction is registered with the Swedish Companies Registration Office. The last day for trading in BTA is anticipated to be around October 16, 2026, after which these will convert to standard shares.

Compensations and Future Considerations

As part of the rights issue, Bergs Securities also provided a guarantee commitment valued at approximately SEK 24.2 million, which incurs a compensation fee calculated either in cash or shares. Depending on the specifics of this arrangement, potential dilution moving forward remains a strategic consideration.

Conclusion

Through this rights issue, SciBase has expressed a renewed commitment to enhancing dermatological care through early detection technologies such as Nevisense, aligning with its broader mission to reduce healthcare costs while improving patient outcomes. As it stands, SciBase’s with strong financial backing equips it to navigate upcoming challenges, including the anticipated transition of leadership and market expansion in the U.S.